MC38-hPSMA (2)
Strain Information
Validation Data
Ⅰ.In vitro Expression of MC38-hPSMA cell line
The hPSMA protein expression in the wild-type MC38 and MC38- hPSMA cells were measured by Flow Cytometry.
Figure 1. hPSMA expression in wild-type MC38 and MC38-hPSMA cell line
Ⅱ. Characterization of in vivo growth kinetics
To test the take rates, and the tumor growth characteristics of MC38-hPSMA cell line, cells were subcutaneously inoculated into the C57BL/6 mice.
Figure 2. Tumor growth curve of MC38-hPSMA syngeneic model
Figure 3. Body weight change of MC38-hPSMA syngeneic model
Ⅲ. Expression of hPSMA protein in tumors
To verify the hPSMA protein expression, the tumors were dissected and separated for single cell suspension.
Figure 4. The expression of hPSMA in humanized modified tumors by FACS
Ⅳ.Efficacy verification
Murine colon cancer MC38-hPSMA cells were subcutaneously implanted into hCD28/hPSMA-C57BL/6 mice. Mice were grouped when tumor volume reached approximately 80-90 mm3, at which time they were treated with CD28×PSMA+mPD-1 antibody indicated in panel.
Figure 5. Antitumor activity of CD28×PSMA+mPD-1 antibody. MC38-hPSMA cells provided a powerful preclinical model for in vivo evaluation
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreAt GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more